Proteon Therapeutics Slumps On Phase III Study Miss In CKD

Shares in Proteon Therapeutics lost nearly three-quarters of their value on news that its first Phase III trial for its lead product vonapanitase had failed. Undeterred, however, the company is increasing the size of its second pivotal study on the back of positive data from certain key endpoints.